‘The U.S. Government [is] pouring more than $3 billion on a neglected area of research: developing pills to fight the virus early in the course of infection, potentially saving many lives in the years to come….A number of other viruses, including influenza, H.I.V. and hepatitis C, can be treated with a simple pill. But despite more than a year of research, no such pill exists to treat someone with a coronavirus infection before it wreaks havoc.”
(J. Harris: These “antibiotics” can and will be developed.)
(J. Harris: From AP is easy to understand format. I’m not sure just what it means, yet.)
FROM HOPKINS CITATIONS:
1. Monoclonal Antibodies Cut Risk of Dying from COVID-19—But Only in Some Patients (Science)The world’s largest trial of COVID-19 therapeutics has for the first time produced convincing evidence that a therapy that directly attacks the virus can save hospitalized patients from death. A combination of antibodies called casirivimab and imdevimab, produced by Regeneron, did not lower mortality when all patients in the study were taken together, investigators of the United Kingdom’s Recovery trial announced today—but it reduced deaths by one-fifth among those who did not produce antibodies themselves. A paper with the results will be made available on the medRxiv preprint server later today, the researchers say.
2. Many Post-Covid Patients Are Experiencing New Medical Problems, Study Finds (New York Times) Hundreds of thousands of Americans have sought medical care for post-Covid health problems that they had not been diagnosed with before becoming infected with the coronavirus, according to the largest study to date of long-term symptoms in Covid-19 patients.
3. A Detailed Study of Patients with Long-Haul COVID (FAIR Health) (J. Harris: This is a detailed Long Haul study of almost 2 million Covid cases. It is in PDF format and you can download it.
FROM BECKERS( they closely follow CDC and many other journals and do nice, succinct reviews which are amazingly pertinent — and you can have them sent directly to you.)
Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo….”
(J. Harris — THIS IS A LETHAL PNEUMONIA: “A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids [as well as Tofacitinib or Placebo] during hospitalization. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group…”)
AND LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.